Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (63)	11/4/2000 8:20:05 PM
From: smh	Respond to of 1784

Don't recall seeing this posted anywhere. kiplinger.com Kiplinger's Magazine September 2000 \| INVESTING \| STOCKS Picks and Shovels The Payoff for Genebusters Picks and Shovels That's where Van Wagoner's Garrabrant is placing his bets. "We favor companies that sell the enabling technology to discover more about what genes do, now that they've been identified," he says. Those include Affymetrix (AFFX), which makes an array of gene-testing computer chips; Gene Logic (GLGC), which conducts tests to discover the proteins made by specific genes; Millennium Pharmaceuticals (MLNM), which both hires itself out to large pharmaceutical companies to find the most promising targets for drug development and develops gene-based drugs in-house; and Applied Biosystems (PEB), which sells instruments, reagents and software used in biotech research. (For more on Applied Biosystems, see Future Stocks.) Von Emster agrees. "Certainly the picks-and-shovels companies will win first," he says. Four such stocks he favors: Abgenix (ABGX), which creates genetically altered mice and flies for use in research, and which develops monoclonal antibodies as potential drugs; Affymetrix; Exelixis (EXEL), which compares gene sequences in animals and humans to hunt down prospective targets for development; Orchid Biosciences (ORCH), which sells basic chemical reagents needed for genetic research; and scientific-equipment maker Waters Corp. (WAT). Of the highlighted companies, only Applied Biosystems and Waters are profitable, although analysts expect Affymetrix to break into the black in the last three months of this year. They also forecast database sellers Incyte Genomics (INCY) and Human Genome Sciences (HGSI) to generate earnings in 2001 and 2002, respectively. But most genomics companies are trading on hopes and dreams, not results. For now, at least, a more sensible way to dip into the genomics industry may come through a biotech sector fund. For more on two of the past year's top-performing biotech funds, see Go Ahead, Play With Fire. Reporter: Otto Krusius

To: tom pope who wrote (63)	11/5/2000 11:05:42 AM
From: tuck	Read Replies (1) \| Respond to of 1784

tom, I'm getting to the point at which I'm going to start nibbling at certain things. Thinking of nibbling MDS on a pull back to ~19. I had a long look at MDS yesterday. They have their fingers in many pies, including canadian distribution deals, CRO work, mass spectrometers, and a venture capital arm that has interests in many companies we're interested in (I like the idea of such companies having a VC unit: maybe it keeps them in better touch with the newer technologies coming down the pike). It seemed reasonably valued relative to its prospects. Rick and I discussed it briefly in the first few posts. Your input is welcome. Sounds like you have an opinion on MDS. Let's hear it! Cheers, Tuck